Lakshmi Nayak, MD presented results from a phase 2 PROSPECT study focused on tirabrutinib and it's effect on patients with relapsed or refractory primary central nervous system lymphoma.
Published
June 11, 2025
Created by
Related Presenters
Neuro-oncology
Dr. Lakshmi Nayak serves as Director of the Center for CNS Lymphoma at Dana-Farber Cancer Institute in Boston. She is an Associate Professor of Neurology at Harvard Medical School. She received her medical degree at Grant Medical College ...